Bayer, Christian M <br/><br/>
Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.  [electronic resource] 

 -  Current opinion in obstetrics & gynecology  02 2017 
 - 4-11 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1473-656X 
<br/><br/><label>Standard No.: </label>10.1097/GCO.0000000000000333  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Bone Density Conservation Agents--pharmacology<br/>Bone Neoplasms--drug therapy<br/>Bone and Bones--drug effects<br/>Breast Neoplasms--genetics<br/>Chemoprevention<br/>Denosumab--pharmacology<br/>Diphosphonates--pharmacology<br/>Female<br/>Genes, BRCA1--physiology<br/>Humans<br/>Osteoprotegerin--metabolism<br/>RANK Ligand--antagonists & inhibitors<br/>Receptor Activator of Nuclear Factor-kappa B--metabolism<br/>Risk